A new trading day began on May 19, 2023, with Pacific Biosciences of California Inc. (NASDAQ: PACB) stock priced at $12.67. During the day, the shares moved up to $12.82 and dropped to $12.405 before settling in for the closing price of $12.67. PACB’s price has ranged from $3.85 to $14.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 6.50% over the past five years. Meanwhile, its annual earnings per share averaged -57.60%. With a float of $206.29 million, this company’s outstanding shares have now reached $242.03 million.
Let’s look at the performance matrix of the company that is accounted for 769 employees. In terms of profitability, gross margin is +38.08, operating margin of -237.58, and the pretax margin is -244.92.
Pacific Biosciences of California Inc. (PACB) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc. is 0.80%, while institutional ownership is 88.90%. The most recent insider transaction that took place on May 18, was worth 65,027. In this transaction the insider of this company sold 5,165 shares at a rate of $12.59, taking the stock ownership to the 107,577 shares. Before that another transaction happened on Mar 15, when Company’s Director sold 7,541 for $8.90, making the entire transaction worth $67,115. This insider now owns 18,795 shares in total.
Pacific Biosciences of California Inc. (PACB) Latest Financial update
In its latest quarterly report, released on 3/30/2023, the company reported earnings of -$0.36 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -244.92 while generating a return on equity of -46.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -57.60% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.00% during the next five years compared to -9.90% drop over the previous five years of trading.
Pacific Biosciences of California Inc. (NASDAQ: PACB) Trading Performance Indicators
Here are Pacific Biosciences of California Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.50. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 23.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.40, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.04 in one year’s time.
Technical Analysis of Pacific Biosciences of California Inc. (PACB)
Pacific Biosciences of California Inc. (NASDAQ: PACB) saw its 5-day average volume 2.95 million, a negative change from its year-to-date volume of 4.0 million. As of the previous 9 days, the stock’s Stochastic %D was 89.02%. Additionally, its Average True Range was 0.65.
During the past 100 days, Pacific Biosciences of California Inc.’s (PACB) raw stochastic average was set at 96.59%, which indicates a significant increase from 90.46% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.57% in the past 14 days, which was lower than the 70.71% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.71, while its 200-day Moving Average is $9.03. Nevertheless, the first resistance level for the watch stands at $12.86 in the near term. At $13.05, the stock is likely to face the second major resistance level. The third major resistance level sits at $13.27. If the price goes on to break the first support level at $12.44, it is likely to go to the next support level at $12.22. The third support level lies at $12.03 if the price breaches the second support level.
Pacific Biosciences of California Inc. (NASDAQ: PACB) Key Stats
With a market capitalization of 3.17 billion, the company has a total of 249,891K Shares Outstanding. Currently, annual sales are 128,300 K while annual income is -314,250 K. The company’s previous quarter sales were 38,900 K while its latest quarter income was -88,020 K.
